Argenica Therapeutics Limited (ASX:AGN) is developing novel neuroprotective therapeutics to reduce brain damage after stroke and other devastating brain injuries

Based on research from The University of Western Australia and the Perron Institute for Neurological and Translational Science, Argenica’s lead candidate ARG-007 aims to protect brain cells and reduce cell death following a stroke, and other types of brain injury, in order to minimise the impact of these conditions and improve patient recovery.

Ultimately, in acute brain injury, our aim is for ARG-007 to be administered by first responders to protect brain tissue against damage during a stroke and other types of acute injury such as severe traumatic brain injury, with further potential to enhance recovery once the injury has taken place. Our investor centre will provide you all the information you need to stay across the details for investing in Argenica Therapeutics (ASX: AGN) as we bring this exciting product to market.